XTELL has launched a commercial biorepository service, bioVAULT, which stores, manages and processes large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development.
Athens, OH (PRWEB) August 5, 2008 -- XTELL announced today the launch of its commercialized, independent biorepository service stemming from its collaborations with The Ohio University Endocrine Diseases Biorepository. XTELL's "bioVAULT" service will provide storage of biological samples derived from human/animal serum and tissues with 100% guaranteed confidentiality. BioVAULT will allow clinicians and researchers alike to facilitate and link patient/family medical history.
XTELL is a biotechnology company founded in 2001, dedicated to both the development of biological specimen storage and electronic medical record software.
A large part of XTELL's success has been from a direct partnership with Ohio University's Diabetes Center in creating a biorepository designed specifically for fundamental and translational research. Samples include DNA, RNA, and protein extracted from blood serum in patients living in a region of the United States with a high prevalence of diabetes and endocrine-related disease. XTELL has developed one of the most advanced diabetes biorepositories of its kind, with a state-of-the-art collection and storage facility.
BioVAULT is now capable of storing, managing and processing large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development, as well as universities. "Biorepositories are now critical in understanding the molecular mechanisms of disease and for the development of new therapeutics, " said Anthony Schwartz, President of XTELL.
XTELL is privately held and located i
Copyright©2008 Vocus, Inc.
All rights reserved